ConductScience.org, home
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
API referenceFor AI assistants

Trial · NCT04884191

Results by group117

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 117

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Spleen Volume Reduction Response (≥ 35%)Pacritinib 100 mg QDEnd of Week 120Participants
Spleen Volume Reduction Response (≥ 35%)Pacritinib 100 mg BIDEnd of Week 122Participants
Spleen Volume Reduction Response (≥ 35%)Pacritinib 200 mg BIDEnd of Week 122Participants
Spleen Volume Reduction Response (≥ 35%)Pacritinib 100 mg QDEnd of Week 240Participants
Spleen Volume Reduction Response (≥ 35%)Pacritinib 100 mg BIDEnd of Week 241Participants
Spleen Volume Reduction Response (≥ 35%)Pacritinib 200 mg BIDEnd of Week 245Participants
Percent Change in Spleen VolumePacritinib 100 mg QDWeek 123.19Standard Deviation 22.613percent change from baseline
Percent Change in Spleen VolumePacritinib 100 mg BIDWeek 126.37Standard Deviation 31.110percent change from baseline
Percent Change in Spleen VolumePacritinib 200 mg BIDWeek 12-3.60Standard Deviation 26.610percent change from baseline
Percent Change in Spleen VolumePacritinib 100 mg QDWeek 24-2.43Standard Deviation 17.608percent change from baseline
Percent Change in Spleen VolumePacritinib 100 mg BIDWeek 240.65Standard Deviation 20.589percent change from baseline
Percent Change in Spleen VolumePacritinib 200 mg BIDWeek 24-11.30Standard Deviation 26.417percent change from baseline
Total Symptom Score AnalysisPacritinib 100 mg QDEnd of Week 121Participants
Total Symptom Score AnalysisPacritinib 100 mg BIDEnd of Week 121Participants
Total Symptom Score AnalysisPacritinib 200 mg BIDEnd of Week 122Participants
Total Symptom Score AnalysisPacritinib 100 mg QDEnd of Week 242Participants
Total Symptom Score AnalysisPacritinib 100 mg BIDEnd of Week 240Participants
Total Symptom Score AnalysisPacritinib 200 mg BIDEnd of Week 242Participants
Patient Global Impression AssessmentPacritinib 100 mg QDWeek 12 - Any Improved17Participants
Patient Global Impression AssessmentPacritinib 100 mg BIDWeek 12 - Any Improved21Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04884191/results

API referenceFor AI assistants